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Abstract 
Amyotrophic lateral sclerosis with cognitive impairment (ALSci) can be characterized by 
pathological inclusions of microtubule associated protein tau (tau) uniquely 
phosphorylated at Thr175 (pThr175-tau). The purpose of this study was to characterize 
the behavioural consequences of expressing a pseudophosphorylated tau mimic of 
pThr175-tau (Thr175Asp-tau) in rat hippocampus. Expression was hypothesized to lead 
to pathological tau fibril formation resulting in cognitive and behavioural deficits. 
Expression was accomplished in female Sprague Dawley rats through stereotactic 
inoculations of recombinant adeno-associated virus (rAAV9) vector with human tau 
gene. Pathological tau fibrillary structures were identified, but behavioural testing up to 
12 months post-surgery revealed no deficits in Thr175Asp-tau group when compared 
with the controls. Control inoculums included: wt-human tau, phosphorylation inhibition 
(Thr175Ala-tau), and green fluorescent protein. There were age-related behavioural 
changes across testing time points. This study serves an important step towards the 
development of an animal model for ALS with cognitive syndromes, which is essential 
for understanding disease progression. 
Key Words: Amyotrophic lateral sclerosis, Frontotemporal Dementia, Tau, Tauopathy, 
ALS-FTD, ALSci, Non-transgenic Rat Model, Behavioural Analysis, Morris Water 
Maze, Open Field, Acoustic Startle Response, rAAV9 
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1. Introduction 
1.1 ALS: Clinical Definition and Symptoms 
Amyotrophic lateral sclerosis (ALS) is an adult onset neurodegenerative disease defined 
by progressive death of upper and lower motor neurons in the central nervous system. 
Motor neuronal cell loss results in progressive paralysis in patients and death generally 
ensues within an average of 3 to 5 years of symptom onset (Factor-Litvak et al. 2013).  
Under normal physiological function, signals from the upper motor neurons in the brain 
are transmitted to the lower motor neurons in the spinal cord and brain stem, which then 
stimulate movement of voluntary muscles. In ALS, however, both upper and lower motor 
neurons progressively degenerate and die. This leads to diffuse loss of motor function 
accompanied by muscle atrophy and ultimately paralysis with death due to respiratory 
failure. Our conventional understanding of ALS is that in the majority of patients, the 
degenerative process of ALS remains restricted to the motor system, sparing modalities 
such as eye motor control, bowel and bladder function. ALS is one of the most common 
neuromuscular diseases worldwide, and all ethnicities and races are affected, with a 
higher prevalence in men over women in the premenopausal period.  
Approximately 90% of ALS cases are sporadic (sALS) and have no clearly associated 
risk factors, while roughly 10% of cases are considered familial (fALS), or inherited 
(Ince et al. 2011). fALS is genetically heterogeneous. Greater than 50% of fALS cases 
can be accounted for by mutations in the genes encoding the following: superoxide 
dismutase I (SOD1), transactive response DNA binding protein 43 kDa (TDP-43), fused 
in sarcoma/ translated in liposarcoma (FUS/TLS), or chromosome 9 open reading frame 
72 (c9orf72) (Fiesel and Kahle 2011; Kwiatkowski et al. 2009; Rollinson et al. 2011). 
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Though ALS is generally considered either sporadic or familial, this boundary is not 
absolute. For instance, up to 10% of clinically sporadic cases of ALS show mutations in 
several of the associated fALS genes, such as SOD1, FUS, and TDP-43 (Alexander et al. 
2002; Chiò et al. 2011; Kirby et al. 2010). In these cases of sALS, the observed genetic 
mutations could be arising as new, sporadic mutations, or may be a result of insufficient 
family history to support a finding of fALS (Ince et al. 2011).  
1.2 ALS and features of frontotemporal dysfunction 
While ALS and frontotemporal lobar degeneration (FTLD) have been considered to be 
independent disorders, there is increasing evidence to suggest that both ALS and FTLD 
overlap in a significant portion of the patient population. Frontotemporal lobar 
degeneration (FTLD) refers to the progressive degeneration of the frontal and temporal 
lobes of the brain. The distributions of pathology throughout those lobes and the 
attendant disruption of their interconnections results in an array of syndromes of 
frontotemporal dysfunction, including frontotemporal dementia (FTD) (Freedman et al., 
1998; Strong et al., 2009). 
While ALS has classically been considered a disease of the motor neurons alone, 
upwards of 50% of patients with ALS are now known to develop features of 
frontotemporal dysfunction (Strong et al., 2009). These syndromes of frontotemporal 
dysfunction can manifest as a behavioural or cognitive impairment (ALSbi, ALSci), a 
dysexecutive syndrome, or a frontotemporal dementia (ALS-FTD) in which cases the 
Neary or Hodge’s criteria for FTD are met (Freedman et al., 1998; Gregory, Orrell, 
Sahakian, & Hodges, 1997; Strong et al., 2009).   
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Each of these clinically defined syndromes is characterized by different criteria. ALSci 
patients exhibit impaired executive functions or verbal fluency, while ALSbi patients 
show behavioural features associated with frontotemporal dysfunction and meet some of 
the Neary or Hodge’s criteria for FTD (Strong et al., 2009). The term ALS-FTD refers to 
a clinical spectrum that includes ALS with behavioural variant FTD (ALS-bvFTD), 
progressive non-fluent aphasia (ALS-PNFA), as well as semantic dementia (ALS-SD) 
(Strong et al. 2009). These ALS-FTD subtypes are defined as follows: bvFTD shows 
impaired executive function determined through neuropsychological assessment, PNFA 
is characterized by effortful speech production, errors in grammar and difficulties in 
retrieving words, whereas SD exhibits naming and word comprehension impairment 
while speech remains fluent and grammatical (Neary et al. 1998). Aside from the 
utilization of the Neary and Hodge’s criteria, further extensive neuropsychological testing 
is, of course, conducted when diagnosing such disorders. These features serve as an 
effective screening process for ALS patients with frontotemporal dysfunctions. 
1.3 ALS and Frontotemporal Degeneration: impact and relevance  
ALS is amongst the most devastating of adult-onset neurodegenerative diseases. The 
concomitant presence of frontotemporal dysfunction further worsens the condition. The 
presence of these frontotemporal syndromes in ALS is associated with a shorter survival 
rate when compared to ALS alone (Murphy et al. 2006). In addition, caregivers of ALS 
patients with neurobehavioural symptoms have been shown to have a lower quality of 
life, increased rates of depression, and undergo a significantly higher burden (Chiò et al. 
2011). Given the peak age of onset of ALS is in the 6
th
 decade of life, higher prevalence 
of ALS are anticipated as the baby boomers age. From an economic standpoint this will 
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result in greater numbers of patients and a greater burden to the health care system in the 
near future.   
1.4 ALS and Frontotemporal Degeneration: common ties 
The frequent clinical overlap of the syndromes of frontotemporal dysfunctions and ALS 
has led to the notion that these disorders may be a continuum (Strong et al. 2009). The 
development of frontotemporal dysfunction can precede, coincide, or follow the motor 
neuron dysfunction of ALS, and there is frequent co-existence between these two 
conditions (Ringholz et al. 2005; Robberecht and Philips 2013). For each new gene 
mutation discovered in fALS there has been a parallel discovery that those genes 
contribute to the pathobiology of FTD. These associated mutations have become 
important in the neuropathological differentiation amongst distinct subtypes of 
frontotemporal syndromes of ALS (Geser et al. 2013; Ince et al. 2011). For example, 
FTD’s are further classified based on whether TDP-43, FUS/TLS, or hexanucleotide 
repeats in c9orf72 are the predominant pathologies (Rohrer et al. 2011). Altogether, this 
has led some to postulate that ALS and FTD are but two states on a single disease 
continuum, based on the genetic linkages provided by these discovered mutations (Ince et 
al. 2011).   
1.5 The function and dysfunction of microtubule associated protein tau  
Conversely, all forms of FTD are divided into those presenting with alterations in the 
microtubule associated protein tau (tau) – known as “tauopathy” – and those that do not. 
Forms of FTD without a tauopathy are those mutations mentioned above (TDP-43, 
FUS/TLS, c9orf72). Approximately 40% of remaining FTD’s have an underlying 
tauopathy. There is abundant evidence of alterations of tau metabolism in FTD’s. These 
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tauopathies include; Pick’s disease, progressive supranuclear palsy (PSP), and 
corticobasal degeneration (Mackenzie and Rademakers 2007). Recently, similar evidence 
of a tauopathy has been observed, in ALS with frontotemporal dysfunctions. This section 
will address the normal function of tau protein, and the abnormalities observed in ALS.  
Tau protein stabilizes the cytoskeleton of a cell (Weingarten et al. 1975). Within nerve 
cells, microtubules run along the axon from the soma to the synaptic terminal and act as 
tracks to facilitate axonal transport (Brown 2003). Axonal transport allows for the 
movement of synaptic vesicles, proteins, lipids, and organelles throughout the neuron and 
is an essential process for proper neuronal functioning (Brown 2003). Tau protein binds 
to, and supports, the microtubules in the axonal processes to prevent microtubule 
breakdown. This binding stabilizes the cytoskeleton of the cell (Weingarten et al. 1975).  
Human tau proteins are translated from chromosome 17q21 (Buee et al. 2000). A total of 
six isoforms of tau exist in the human adult brain as a result of alternative splicing of N-
terminus domains (N1, or N2) and a C-terminus multiphosphorylation repeat (R2, Figure 
1, Buee et al., 2000).  N1, N2, and R2 are exon 2, 3, and 10 encoded respectively. Each 
can either be included, or not, through alternative splicing (Buee et al. 2000). There are 
three other multiphosphorylation repeats (R1, R3, R4) always present (Buee et al. 2000). 
Thus, there are the 3R or 4R isoforms, containing 0, 1, or 2 N-terminus inserts for a total 
of six isoforms of tau (in order of increasing size): 0N3R, 0N4R, 1N3R, 1N4R, 2N3R, 
2N4R. The smallest isoform, 0N3R, has a molecular weight of 36.7 kDa, whereas the 
largest, 2N4R, has a molecular weight of 45.9 kDa (Mandelkow and Mandelkow 2012). 
The isoforms with more repeats, like 2N4R, tend to bind more strongly to microtubules 
than shorter isoforms, such as 0N3R (Mandelkow and Mandelkow 2012).  
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A tauopathy is a diseased state where tau protein becomes hyperphosphorylated, loses its 
affinity for the microtubule, forms aggregates, and relocates then from the axon to the 
cell body (Kowall and Kosik 1987). Tau protein aggregation is a pathological hallmark 
for a number of neurodegenerative diseases such as Pick’s disease, PSP, and Alzheimer’s 
disease (Ferrer et al. 2005). The prominence of tau pathology in these neurodegenerative 
diseases has been taken to suggest that tau protein abnormalities are linked to 
mechanisms of brain degeneration.  
The normal function of tau is physiologically regulated by phosphorylation. Normal 
physiological changes in the phosphorylation state of tau protein can be observed during 
development. Specifically, the phosphorylation state of tau is high in fetal stages, and 
decreases with age as a result of activation of phosphatases (Mawal-dewan et al. 1994; 
Vanmechelen et al. 1995). In the fetal state, tau is hyperphosphorylated, containing  
approximately four phosphates per tau molecule, whereas adult tau contains roughly two 
phosphates per tau molecule (Mandelkow and Mandelkow 2012). In either case, tau is 
extensively phosphorylated. As such, hyperphosphorylation of tau protein is not a total 
indicator of a disease state (Mandelkow and Mandelkow 2012).  
There is a complex balance between phosphorylation and dephosphorylation. This 
complex balance results from the activity of specific kinases and phosphatases towards 
the phosphorylation sites within or outside the microtubule-binding domain (Hasegawas 
et al. 1992; Paudel and Li 1999; Roder et al. 1997; Takahashi et al. 1995; Vanmechelen 
et al. 1995). Ultimately, under normal physiological conditions there is a complex 
balance of phosphorylation and dephosphorylation of tau protein, and it is not simply 
phosphorylation of tau that leads to a diseased state. Rather, it may be the abnormal 
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phosphorylation of tau, and consequent loss of affinity for the microtubule, that leads to a 
disease state. 
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Figure 1: Schematic of human tau protein isoforms 
The sizes of the tau isoforms range from 352 to 441 amino acids. Their molecular 
weights range from 36.7 to 45.9 kDa, with the tau variants differing from each 
other by the presence of either three (R1, R3, R4) or four repeat regions (R1, R2, 
R3, R4) in the C-terminal part of the molecule, as well as the presence or absence 
of one or two inserts (E2, E3) in the N-terminal part (Mandelkow and 
Mandelkow 2012).  
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1.7 Propagation of tau pathology  
As previously stated, pathologically phosphorylated tau is a prominent component of the 
intracellular inclusions of many neurodegenerative diseases. In ALSci, it has been 
proposed that neuronal and glial tau inclusions first appear in the entorhinal cortex, and 
that this then forms the apparent epicenter of pathology (Yang & Strong, 2012).  It has 
been further proposed that from the entorhinal cortex the tau pathology spreads to regions 
such as the superior frontal and anterior cingulate cortex, regions of the hippocampus, the 
substantia nigra, and the basal ganglia (Nakano, Nakaso, and Nakashima 2004; Yang and 
Strong 2012). 
There is evidence of this described propagation of tau pathology from animal model 
studies. A neuropsin-tTA-tau transgenic mouse model with inducible expression of 
pathological human tau in the entorhinal cortex was established. This model showed 
changes in the distribution of tau pathology at different time points (Liu et al. 2012). 
Relatively young (10-11 months old) transgenic mice showed tau pathology mostly 
limited to the entorhinal cortex, whereas aged transgenic mice (>22 months old) 
demonstrated evidence of trans-synaptic propagations of tau accompanied by mature 
tangle formation along anatomically connected neurons (Liu et al. 2012).  
1.8 ALS with cognitive impairment (ALSci) 
The most commonly impaired functions in ALSci patients are verbal fluency, visual 
memory, immediate verbal memory and executive dysfunction (Raaphorst et al. 2010). 
Although tau pathology is only rarely observed in motor neurons in ALS, there is 
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abundant evidence of disturbances in tau metabolism in cortical and subcortical neurons 
in ALSci.  
At a tissue level, ALSci is characterized by a spectrum of neuropathological 
abnormalities including gross frontal atrophy, and superficial linear spongiosis (SLS) in 
the frontal cortex (Wilson et al. 2001).  There are also neuronal and glial tau protein 
inclusions located most prominently in the entorhinal cortex, hippocampus, and anterior 
cingulate gyrus (Yang et al. 2003). Tau protein aggregation in the frontal cortex is a 
disease-specific process as opposed to a normal function of aging (Yang, Ang, and 
Strong 2005). Further, tau isolated from the cortical and subcortical white matter of 
cognitively impaired ALS patients is highly insoluble and tends to form pathological 
fibrils ex vivo (Strong et al. 2006). These tau fibrillary inclusions in ALSci are aberrantly 
phosphorylated at Threonine residue 175 (pThr175) and associated with an upregulation 
of GSK3β activity (Strong et al. 2006; Yang, Leystra-Lantz, and Strong 2008; Yang and 
Strong 2012). The extent of fibril formation, as well as aberrant phosphorylation, is 
significantly greater in ALSci-derived tau than in controls, with ALS-derived tau falling 
intermediately between these (Strong et al. 2006). These observations suggest that 
aberrant phosphorylation of tau may be a common occurrence in ALS (Behrouzi et al. 
2016; Yang and Strong 2012).  
1.9 In vitro effects of pseudophosphorylated (Thr175Asp-tau) tau  
To investigate the above-mentioned tau pathology, full-length tau constructs were 
subjected to site-directed mutagenesis to replace Thr175 with either aspartic acid (Asp) or 
alanine (Ala). The expression of Asp at Thr175 (Thr175Asp-tau) mimics Thr175 
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phosphorylation, whereas expression of Ala at Thr175 (Thr175Ala-tau) causes inhibition 
of Thr175 phosphorylation (Gohar et al. 2009). This model of pseudophosphorylated tau 
(Thr175Asp-tau) has been shown to induce tau aggregate formation in human embryonic 
cells (HEK293T) and Neuro2A cells at 24, 48, and 72 hours post-plating (Gohar et al. 
2009). Additionally, it was found that the 2N4R tau isoform shows the greatest tendency 
for fibril formation (Gohar et al. 2009).With pseudophosphorylation of tau, there is an 
enhanced rate of caspase-mediated cell death 96 hours post-plating (Gohar et al. 2009). 
Using the construct that inhibits phosphorylation at Thr175 (Thr175Ala-tau), has 
conversely been shown to significantly inhibit aggregate formation (Gohar et al. 2009). 
These in vitro findings suggest that phosphorylation of Thr175 on tau is pathologically 
relevant to ALSci (Moszczynski et al. 2015).  
1.10 A potential mechanism of tau pathology in ALSci 
The normal or abnormal function of tau is regulated by the phosphorylation of specific 
sites along the protein (Forman, Trojanowski, and Lee 2004). For example, 
phosphorylation of tau at Threonine residue 231 (Thr231) by the well-established tau 
kinase glycogen synthase kinase-3β (GSK3β) plays a major role in regulating the binding 
of tau to microtubules (Cho and Johnson 2004). GSK3β activation has been linked to tau 
pathology, and its subsequent phosphorylation of Thr231 is known to cause a 
conformational change in tau decreasing its ability to bind microtubules (Cho and 
Johnson 2004; Lin et al. 2007). It has been shown in vitro that Thr175Asp-tau induces 
GSK3β phosphorylation and activation, which in turn induces Thr231 phosphorylation 
and the formation of pathological intracellular tau fibrils  (Moszczynski et al. 2015). Of 
direct relevance to ALSci, inhibition of GSK3β activity reduced both fibril formation and 
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cell death in Thr175Asp-tau transfected cells indicating a role of GSK3β in fibril 
formation (Moszczynski et al. 2015). Based on these in vitro results, a potential 
mechanism is proposed where pThr175-tau induces GSK3β activation, which leads to 
Thr231 phosphorylation and subsequent fibril formation (Moszczynski et al. 2015). 
1.11 Animal models of neurodegeneration 
Animal models play an important role in our understanding of the pathogenesis of 
neurodegenerative diseases such as tauopathies and ALS. They also provide the basis for 
developing and testing potential therapeutic agents for such diseases. 
Transgenic mice and rat models of pathological tau deposition have been developed to 
examine the role of tau in human neurodegenerative diseases. Tau transgenic mice 
expressing the smallest human tau isoform under the PrP promotor develop an age-
dependent tauopathy pathology (Ishihara et al. 1999). Ishihara et al. found that the 
tauopathy included tau-immunoreactive intraneuronal inclusions in cortical, brainstem 
and spinal cord motor neurons in association with progressive motor neuron degeneration 
(1999). These latter authors subsequently demonstrated progression of the tau pathology 
with increasing age  (Ishihara et al. 2001). Similar expression of the smallest tau isoform 
in transgenic mice, while not inducing neurofibrillary tangles even at 19 months of age, 
did induce ‘pretangle’ tau deposition with immunoreactivity to several pathological tau 
phosphorylation sites observed in human neurofibrillary tangles (Brion and Tremp 1999). 
Taken as a whole, these studies reveal that transgenic models are effective for the 
investigation of tauopathies and neurodegenerative disease, and that a significant amount 
of time may be required to lead to measurable neurodegeneration.  
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There is also abundant evidence in rat models demonstrating the development of 
behavioural and neuropathological features consistent with a tauopathy in a wide range of 
paradigms. For example, transgenic rats expressing truncated human tau protein showed a 
progressive behavioural impairment, and widespread hyperphosphorylated tau deposits 
(Zilka et al. 2006, 2010). In another study, transgenic rats expressing Alzheimer’s 
disease-associated tauP301L displayed prominent dendritic pathology (Korhonen et al. 
2011).  In summary, there have been a number of studies that were successful in 
developing transgenic mice and rat models that mimic pathologies observed in humans. 
However it is important to note that such models also present with the drawbacks of late 
onset, and lack of expression control. 
As an alternative to transgenic models, somatic gene transfer by viral vectors is a method 
used extensively in animal studies. This method leads to efficient expression of a protein 
of interest in defined neuronal populations (Klein, Wang, and King 2009; McCown 
2005). The recombinant adeno-associated viral vector serotype 9 (rAAV9) has been 
shown to produce the greatest expression in the neurons of the CNS with a reporter gene 
such as green fluorescent protein (GFP) and with neurodegenerative disease-related tau 
protein in comparison to other AAV serotypes (Klein et al. 2006, 2008). This allows for 
the ability to induce expression of the protein of interest at specific ages, which is 
especially beneficial to produce age-related models of neurodegenerative diseases (Klein 
et al. 2010). Ultimately, the somatic gene transfer technique, using rAAV viral vector, 
offers the benefits of being able to control the expression of the protein of interest in 
region-specific and age-specific ways.   
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1.12 Expression of tau constructs in the hippocampus 
The cognitive and behavioural studies, for which this thesis reflects, involve of the use of 
somatic gene transfer using the rAAV9 viral vector to express a range of human tau 
constructs in the adult Sprague Dawley rat hippocampus (Strong Lab, unpublished data). 
The hippocampus was the targeted brain region because of the range of substantiated 
behavioural paradigms that serve to indicate abnormalities in hippocampal function of 
animal models. There were four inoculums used in the study including: an aberrantly 
phosphorylate tau mimic (Thr175Asp-tau); Thr175Ala-tau in which phosphorylation at 
Thr175 is inhibited; wt-tau; and EGFP controls. Each of these tau constructs was tagged 
with EGFP.   
EGFP expression was confirmed in the hippocampus of all four treatment groups (wt-tau, 
Th175Asp-tau, Thr175Ala-tau, EGFP) for the entirety of the study (12 months post-
surgery, Figure 2, Figure 3, Strong Lab, unpublished data). This indicated that the rAAV9 
viral vector was effective for the expression of the human tau protein constructs in the 
hippocampus of the rat host. Expression was specific to the hippocampus (the structure of 
injection) as there was no EGFP expression in the cerebellum or thalamus (Figure 2, 
Strong Lab, unpublished data). However, there was variability in expression of the viral 
constructs throughout the hippocampal structure, as observed in Figure 5 (Strong Lab, 
unpublished data).  
Additionally, tau fibrillary structures were identified at 3 months post-surgery in the 
experimental (Thr175Asp-tau) group (Figure 4, Strong Lab, unpublished data). The 
extent of the pathology and frequency within groups is not yet known.  
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Figure 2: Hippocampal expression of EGFP-tagged rAAV9 Thr175Ala-tau 
at 1 month post-surgery 
Rabbit anti-GFP 1:200 DAB stain. (A) Section from a Thr175Ala-tau injected rat 
brain at 1 month post-surgery confirms expression of the viral vector in neurons 
of the hippocampus. Section from a Thr175Asp-tau injected rat brain at 3 months 
post-surgery shows (B) no expression of EGFP in the cerebellum, and (C) no 
expression of EGFP in the thalamus. 
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Figure 3: Expression of EGFP in all four treatment groups at 12 months 
post-surgery 
Rabbit anti-GFP 1:200 DAB stains. Sections from (A) wt-tau injected rat 
hippocampus, (B) Thr175Asp-tau injected rat hippocampus, (C) Thr175Ala-tau 
injected rat hippocampus, and (D) an EGFP injected rat hippocampus. Each brain 
was collected 12 months post-surgery. These images confirm expression of the 
viral vector in the hippocampus. 
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Figure 4: Expression of tau fibrillary structures in Thr175Asp-tau 
expressing rats 
Rabbit anti-GFP 1:200 DAB stain. Section from a Thr175Asp-tau injected rat 
brain at 3 months post-surgery. (A) Tau fibril with corkscrew pathology, (B) tau 
fibrillary structure.  
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Figure 5: Variable expression of EGFP-tagged rAAV9 Thr175Asp-tau  
Rabbit anti-GFP 1:200 DAB stain. Section from a Thr175Asp-tau injected rat 
brain at 3 months post-surgery. Expression is observed in the dentate gyrus (DG), 
and in CA3-CA2 regions, but not in the CA1 region.  
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1.13 Rationale 
It has been established that significant proportions of ALS patients either present with, or 
develop frontotemporal dysfunction, whether it be ALSbi, ALSci or ALS-FTD. These 
neuropsychological deficits are also associated with shorter patient survival and an 
increased caregiver burden and depression. Previous observations reveal neuronal and 
extraneuronal tau depositions in ALSci with a unique tau phosphorylation site at 
Threonine residue 175 (pThr175-tau), which has led to the postulation that ALSci can be 
associated with alterations in tau metabolism. It is also known that pseudophosphorylated 
tau (Thr175Asp-tau) induces tau aggregate formation and increased cell death in vitro 
(Gohar et al. 2009). The effects of pThr175-tau have not been investigated in vivo. 
Therefore, the purpose of this study is to investigate the effects of expressing 
pseudophosphorylated tau (Thr175Asp-tau) in a rat model and characterize its 
pathological and behavioural consequences.  
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1.14 Hypothesis and Aims 
Hypothesis: 
Expression of aberrantly phosphorylated tau protein at pThr175 in the hippocampus leads 
to cognitive and behavioural deficits.  
Aim: 
Characterize the behavioural effects of expressing aberrantly phosphorylated (human 
2N4R) tau at Threonine residue 175 (Thr175Asp-tau) in rat hippocampus by evaluating 
the effects on different hippocampus-related cognitive tasks, such as spatial learning and 
memory, exploratory and anxiety-like behaviour, as well as sensory filtering, and 
sensorimotor gating at 1, 3, 6, 9, and 12 month post-surgery time points. 
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2. Methodology 
2.1 Stereotactic Injections and tau protein constructs 
Somatic gene transfer 
A somatic gene transfer technique was used to express recombinant adeno-associated 
virus (rAAV9) vectors: rAAV9 tau (wt-human tau), rAAV9 Thr175Alanine-tau 
(phosphorylation inhibition), rAAV9 Thr175Aspartic-tau (phosphorylation mimic), 
rAAV9 EGFP (control) in the hippocampus of wild-type female Sprague Dawley rats 
(Figure 6).  
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Figure 6: rAAV9 constructs injected as different treatment groups 
Recombinant adeno-associated virus (rAAV9) vectors incorporating green 
fluorescent protein (EGFP) and 2N4R human tau. From top to bottom the 
constructs are as follows: rAAV9 tau (wt-human tau), rAAV9 Thr175Alanine-tau 
(phosphorylation inhibition), rAAV9 Thr175Aspartic-tau (phosphorylation 
mimic), rAAV9 EGFP (control). 
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Stereotactic injections procedure 
All procedures followed the guidelines of Canadian Council on Animal Care and Western 
University Animal Use Subcommittee. Two-month old wild type female Sprague Dawley 
rats (Charles River Canada) were housed in pairs prior to surgery and randomly assigned 
to an experimental or control group. Food and water were provided ad libitum. Ten rats 
were used per inoculum, thus a total of 40 rats underwent surgery. Each rat weighed 
approximately 250 g at the time of surgery. All rats in this study were female because of 
a planned follow-up study which will utilize a double transgenic rat line that exhibits X-
chromosome-linked transmission of the transgene of interest (further detail in ‘Future 
Studies’ section of Discussion).  
Rats were weighed, anesthetized under an induction dose of 5% isofluorane and 2 L/min 
oxygen, and shaved at the top of their heads. With a stereotaxic apparatus, their heads 
were immobilized using ear bars as well as a mouth-piece. A plastic mask covered the 
nose and delivered a maintenance dose of 2.5% isoflurane anesthetic with 1% oxygen. 
Eye lube was applied to the eyes to avoid them from drying out during the procedure, and 
the bald area of the head was disinfected using a three-stage preparation: rub with soap, 
then ethanol, and finally iodine. Body temperature was maintained by placing a 37˚C 
isothermal pad beneath the rat for the duration of the procedure. A rostrocaudal incision 
was made along the midline of the scalp, and the subcutaneous tissue and periosteum 
were elevated to expose the underlying bone. Four small holes (1mm) were bored into the 
skull using an electric drill. Injections of the rAAV9 vectors were conducted using 
stereotactic coordinates, with Bregma as the reference point. Four inoculations per animal 
were conducted at two sites per side (3 µL per site), all within the hippocampus at the 
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following coordinates: A/P: -5.5 mm, M/L: ±4.6 mm with D/V: -3.2 mm, and M/L: ±6.0 
with D/V: -6.0 mm (Figure 7). Using Hamilton syringes, a total volume of 12 µL (3 µL 
per site) injected over the course of 20 minutes (5 minutes per site) were injected for a 
total of 1.32 x 10
10
 vector genomes. After the injection, the syringe tip remained in place 
for 2 minutes, before being slowly withdrawn. The coordinates and vector volume were 
adopted from Mustroph et al. (2012).  
Rats were then sutured and administered 0.1 mL/100 g Baytril, and 0.1 mL/100 g 
Meloxicam subcutaneously. After surgery, rats were placed in a recovery cage under a 
heat lamp until fully recovered from the anesthesia. Rats were then singly housed for 1 
week to allow for the incision to close, and then were paired with another rat.   
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Figure 7: Stereotactic coordinates represented on cross-section of rat brain 
Injection sites in the rat hippocampus; 4 injection sites with 3 µL injected into 
each site (total of 12 µL per rat).  The injection coordinates from Bregma are as 
follows: left lateral injection; A/P: -5.5 mm, M/L: +6.0 mm, D/V: -6.0 mm, left 
medial injection; A/P: -5.5 mm, M/L: +4.6 mm with D/V: -3.2 mm, right lateral 
injection; A/P: -5.5 mm, M/L: -6.0 mm, D/V: -6.0 mm, right medial injection; 
A/P: -5.5 mm, M/L: -4.6 mm with D/V: -3.2 mm.  
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2.2 Behavioural Testing  
Open Field Testing  
The open field test (OFT) was used to determine exploratory behaviour and to provide a 
measure of potential anxiety-like behaviour. Animals were placed in the testing room at 
least 1 hour before testing. The open field is a square enclosure 45.7 cm x 45.7 cm with 
surrounding walls 40.6 cm high that prevent escape (Figure 8). The open field boxes were 
divided into two zones: the center is defined by a conceptual square of approximately 
27.5 x 27.5 cm, and the periphery by the perimeter of the box (Figure 8). The open field 
boxes were cleaned with 95% ethanol before testing, and between each test session to 
remove any scent of urine and feces. Rats were placed in the open field box for 30 
minutes and monitored by an overhead camera. The analysis of activity was performed 
using ANY-MAZE software version 4.82. The total time spent moving, the distance 
traveled, as well as the time spent in each zone was analyzed.  
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Figure 8: Open field test (OFT) box schematic 
Overhead schematic of the open field test (OFT) box. The open field is a square 
enclosure 45.7 cm x 45.7 cm with surrounding walls 40.6 cm high that prevent 
escape. The center is defined by a conceptual square of approximately 27.5 x 
27.5 cm.  
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Acoustic Startle Response  
The acoustic startle response (ASR) was measured to analyze sensory filtering, and 
sensorimotor gating. To measure the ASR, Med Associate startle boxes were used 
(Figure 9). These sound-proof boxes contain a force plate on which the rats are placed, 
and the whole-body startle response results in the vertical dislocation of the platform. 
This vertical dislocation of the platform is transduced into a voltage and translated to 
digital startle amplitude readout on a computer for data analysis. Before placement on the 
platform, rats were placed in a clear cylindrical plastic tube to prevent escape from the 
platform. The tubes contain bored holes to allow the sounds from the speakers (startle 
stimuli) within the boxes to be heard without being muffled by the clear cylinder.  
An acclimation phase was used for the rat to adapt to the animal holder and startle box 
with background noise. During a 5 minute acclimation period, the rat was placed in the 
cylindrical tube, placed in the startle box, and presented with constant background noise 
of 65 dB white noise with no startle stimuli. This lasted a total of 5 minutes.  
Next, an input/output (i/o) function was established for each individual rat tested. This 
started with a 5 minute acclimation period, followed by 12 startle stimuli of 20 ms white 
noise and increasing intensity from 65 dB to 120 dB in 5 dB steps, with an interstimulus 
interval of 15 seconds. The readout of the startle response amplitude gives the 
experimenter an idea of each animal’s startle intensity. With this information, the 
experimenter can increase or decrease the sensitivity of the platform if the animal has low 
or high startle intensity, respectively. This i/o function protocol lasts a total of 9 minutes, 
with the white background noise continuing through the entirety of the test.  
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For assessing sensory filtering and sensorimotor gating, short-term habituation (STH) and 
prepulse inhibition (PPI) were measured respectively, within the following startle testing 
protocol. It started with a 5 minute acclimation period, followed by Block I: Habituation, 
and Block II: PPI. Block I contained 50 startle stimuli that consisted of a white noise of 
20 ms duration and 110 dB intensity, with an interstimulus interval of 20 sec. Block II 
consisted of pseudorandomized trials of startle stimuli with and without a prepulse. The 
prepulse was a white noise of 4 ms duration with either 75 or 85 dB intensity, preceding 
the startle stimulus by either 30 or 100 ms. The pseudorandomized trials are as follows:  
 10 startle stimuli with no prepulse 
 10 startle stimuli with prepulse at 75 dB and ISI of 30 ms 
 10 startle stimuli with prepulse at 75 dB and ISI of 100 ms 
 10 startle stimuli with prepulse at 85 dB and ISI of 30 ms 
 10 startle stimuli with prepulse at 85 dB and ISI of 100 ms 
This adds to a total of 50 trials in Block II and lasted 31 minutes, with the white 65 dB 
background noise continuing through the entire test. The startle testing lasted over 3 days 
in order to acclimate the animal to the startle boxes, to establish an input/output (i/o) 
function, and to actually test the animals. The protocol outline was as follows:    
 Day 1: Acclimation  2 hour break (minimum) Acclimation  
 Day 2: Acclimation  2 hour break (minimum)  i/o function  
o The i/o function establishes the Gain for each rat to be used on Startle 
testing 
 Day 3: Startle (STH and PPI) 
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Figure 9: Med Associates acoustic startle box 
Photograph of a Med Associates startle box. Inside at the back of the box is a 
speaker, with the platform in front of it. The rat is placed in a clear, plastic tube 
before being placed on the platform. To the right of the platform are the knobs 
for calibrating the box and setting the Gain for each rat. The two swivel doors on 
the front are closed during testing.  
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Morris Water Maze (MWM) 
The MWM task was used to assess spatial learning and memory in the four groups of rats 
in this study. The water maze consisted of a circular pool with a depth of 58 cm, and 145 
cm in diameter, which was conceptually divided into four quadrants (Q1, Q2, Q3, Q4) 
using cardinal coordinates North, East, South and West (not the true magnetic 
coordinates, Figure 10). The pool was filled with water (20-23˚C to a depth of 33 cm) and 
turned opaque using black dye. In one of the quadrants a hidden, movable, transparent 
circular acrylic platform of 11.4 cm diameter was placed in the pool 1-2 cm below the 
water surface. The quadrant containing the platform was referred to as the target 
quadrant. Distinctive, distal visual cues were placed on the walls of the room at each 
cardinal coordinate for facilitating the spatial orientation of the animal. Animals were 
placed in the testing room at least 1 hour before testing on each day of testing.  
To test spatial learning, the platform location remained constant in one quadrant. The rats 
were trained in 4 trials per day for 4 consecutive days. For each trial, the rat was placed in 
a different start location around the pool and allowed 60 seconds to find the hidden 
platform. If the rat did not find the platform in the allotted 60 seconds, it was gently 
guided to the platform. The rat was allowed 15 seconds on the platform for each trial 
before being picked up. Each trial was recorded with a camera, and the analysis of 
activity was performed using ANY-MAZE software version 4.82. The average of the 
time taken to find the platform during the 4 trials was calculated for each of the 4 days to 
compare performance over the 4 days of learning. The performance of the spatial learning 
task was expressed in terms of latency and distance traveled to find the platform. 
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To test reference memory, a single probe trial was conducted on the 5
th
 day of testing (24 
hours after the 4
th
 spatial learning trial) where the hidden platform was removed from the 
pool. The rat was placed in the pool at a novel start location and allowed to swim for 30 
seconds. The distance traveled and the time spent within the target quadrant, as well as an 
area surrounding where the platform was during the learning trials, were measured during 
the 30 seconds of swimming. An area larger than the area of the actual platform (twice 
the diameter of the platform) was used in the analysis to account for the fact that the 
computer tracking system considers the rat as a single point, as opposed to observing the 
rat’s whole body. Note that the time spent in the area where the platform was during the 
learning trials is a more specific index of spatial location compared to the time spent 
within the target quadrant.  
The protocol for MWM testing was altered at different time points (adding to the original 
protocol used at month 1 post-surgery), using tests with increasing sensitivity. Specific 
changes to the protocol were as follows: a probe trial 7 days after the first probe trial was 
added to test long-term memory for months 6 and 9 post-surgery, and reversal learning 
was added to the month 12 post-surgery time point. The long-term memory test was not 
conducted at month 12 because the reversal learning protocol interfered with the long-
term protocol, and the previous long-term results had been inconclusive. The test for 
LTM may have been compromised by the fact that other behavioural tasks were 
conducted during the 7 days between the probe trials. The different MWM protocols for 
all time points are summarized briefly below:    
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Time point MWM Protocol outline 
 
 
Month 1  4 days learning 
 Probe day 5 
 
 
Month 3  4 days learning 
 Probe day 5 
 
 
Month 6  4 days learning 
 Probe day 5 
 Probe day 12 
 
 
Month 9  4 days learning 
 Probe day 5 
 Probe day 12 
 
 
Month 12  4 days learning 
 Probe day 5a 
 Reinforcement day 5b 
 Reversal learning day 6a 
 Reversal learning day 6b 
 Reversal probe day 7  
 
Each time point had a different platform location than the previous time point. The 
experimentation was performed and the data was collected and analyzed by an individual 
blind to the experiment. All experimentation was carried out during the light cycle.  
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Figure 10: Morris Water Maze schematic 
Overhead schematic of the Morris water maze (MWM). The MWM consists of a 
circular pool of 145 cm in diameter; conceptually divided into 4 quadrants (Q1, 
Q2, Q3, and Q4) using cardinal coordinates North, East, South and West (not the 
true magnetic coordinates). This pool is filled with water (20-23˚C to a depth of 
33 cm) and turned opaque using black dye. In one of the quadrants a hidden, 
movable, transparent circular acrylic platform (P) of 11.4 cm in diameter is 
placed in the pool 1-2 cm below the water surface. The quadrant containing the 
platform is referred to as the target quadrant (Q4 in the schematic). Distinctive, 
distal visual cues were placed on the walls of the room at each cardinal 
coordinate for facilitating the spatial orientation of the animal (represented by the 
different shapes of varying colours in the schematic).  
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2.3 Statistical Analysis 
IBM SPSS Statistics 20 was used for statistical analysis. Data are expressed as group 
means (groups are defined by the four treatments) ± the standard error of the mean 
(SEM). Student’s t-tests, one-way, and two-way analysis of variance (ANOVA) testing 
were used where appropriate. Repeated measures ANOVA were also used to compare 
groups. These tests were followed by post hoc tests and Bonferroni corrections. The 
symbol “ * ” indicates statistical significance between group means (p<0.05).  
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3. Results 
3.1 Changes in n-values across testing time points as a result of aging 
Rats were subjected to behavioural testing at 1, 3, 6, 9, and 12 month post-surgery time 
points. There was an age-related decline in the health of the rats in this study. This lead to 
the death of many rats in the different treatment groups at various time points (Table 1). 
Some lethal health issues included respiratory disease, as well as tumours in a range of 
anatomical locations. Further details of health-related issues are outlined in the ‘Study 
Limitations’ section of the Discussion.   
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Table 1: animal treatment groups and their respective n-values at the given 
testing time points. 
 Behaviour testing time point 
Month 1 Month 3 Month 6 Month 9 Month 12 
Wt-tau n=10 n=10 n=10 n=7 n=6 
Thr175Asp-tau n=10 n=10 n=9 n=8 n=7 
Thr175Ala-tau n=9 n=9 n=9 n=9 n=8 
EGFP n=10 n=9 n=9 n=9 n=9 
 
Months refer to the number of months post-surgery. The sample size (n value) of 
each treatment group changed across testing time points. This occurred due to the 
death of rats typically from health related issues (refer to ‘Study Limitations’ 
section in Discussion for more details).   
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3.2 Open Field Testing Results 
3.2.1 Normal habituation of exploratory behaviour in all groups at all time points 
Rats were subjected to open field testing (OFT) at 1, 3, 6, 9, and 12 month post-surgery 
time points to examine exploratory and anxiety-like behaviour. The rats were tracked 
over a time period of 30 minutes in the open field box, and data was separated into 5 
minute blocks. One rat had to be excluded from analysis since the video tracking system 
did not track it properly. Repeated measures ANOVA showed an effect of block numbers 
(F(5,25)=91.257, p<0.01), but not of treatment (F(3,25)=0.094, p=0.963), or interaction 
of the two factors (F(15,25)=0.847, p=0.624), indicating that all groups habituated 
without significant differences in locomotion between groups. This was the case at all 
behavioural testing time points (representative graphs at Month 12 testing shown, Figure 
11).  
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Figure 11: Ambulatory distance traveled over 30 minutes in OF box at 12 
months post-surgery 
Rats expressing either wt-tau (n=6), Thr175Asp-tau (n=7), Thr175Ala-tau (n=8), 
EGFP (n=9). Each Block represents 5 minutes (total of 30 minutes inside the OF 
box). The figure shows a trend of decreased activity as time progressed for each 
group. Data are expressed as means ± SEM.  
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3.2.2 Total distance traveled by each treatment group across all time points 
The total distances traveled at each time point was analyzed, however a different testing 
location with different open field boxes were used for the first two versus the latter three 
time points. As such, the distance traveled for months 1 and 3 cannot be compared with 
subsequent time points. When comparing total distance traveled there was a significant 
decrease in the total distance traveled between months 6-12, with no significant 
difference between the treatment groups (Figure 12). Two-way ANOVA revealed a 
significant effect of time point on total distance (F(3,87)=19.560, p<0.01), with no 
significant differences between treatment groups across time points (F(6,87)=0.729, 
p=0.628) for the 6-12 month time periods.   
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Figure 12: Total distance traveled in open field test at all time points 
Rats expressing either wt-tau, Thr175Asp-tau, Thr175Ala-tau, EGFP (refer to 
Table 1 for n values). This graph shows the total distance traveled by each 
treatment group at (A) months 1 and 3, and (B) months 6, 9, and 12 of testing in 
the OFT. (B) There was a significant effect of total distance in terms of time 
points, with no significant differences between treatment groups across time 
points. Data are expressed as means ± SEM. * indicates statistical significance, p 
< 0.05.  
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3.2.3 No anxiety-like behaviour indicated between treatment groups at any time 
point 
The ratio of distance traveled in the center of the box versus wall of the box is an 
indication for anxiety-like behaviour, since anxious animals tend to stay close to the 
walls. ANOVA revealed no significant difference between treatment groups at any of the 
time points (F(3,26)=0.177, p=0.911), indicating no differences in anxiety-like behaviour 
(representative graphs at Month 12 testing shown, Figure 13).  
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Figure 13: Center to wall ratio as an Anxiety measure at month 12 
Rats expressing either wt-tau (n=6), Thr175Asp-tau (n=7), Thr175Ala-tau (n=8), 
EGFP (n=9). Open field test data at 12 months post-surgery. All four treatments 
showed a strong preference for the periphery of the open field box as opposed to 
the center of the box, with no statistically significant differences in the ratio of 
center to wall distance traveled between the four treatment groups. Data are 
expressed as means ± SEM.  
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3.3 Startle Reflex Results 
3.3.1 Habituation of the acoustic startle reflex (ASR) 
The amplitude of startle in response to an acoustic stimulus at months 3, 6, 9 and 12 post-
surgery was measured to assess short-term habituation and prepulse inhibition as a 
measure for sensory filtering and sensorimotor gating, respectively. Habituation of the 
startle response was analyzed over 50 trials. Figure 14 depicts absolute startle amplitudes 
over 50 trials at the 3-12 month time points. All groups show habituation to the acoustic 
startle stimuli over the repeated trials at every time point (Figure 14). Repeated measures 
ANOVA revealed habituation to the 50 acoustic stimuli, without significant interactions 
of trial and treatment groups, and without significant differences between the four 
treatment groups at all time points. At month 3, treatment groups showed habituation 
(F(49, 1666)=2.674, p<0.01), no significant interaction of trials and treatment groups 
(F(147, 1666)=0.793, p=0.965), and no significant differences between the treatment 
groups (F(3, 34)=0.118,p=0.949). At month 6, treatment groups showed habituation 
(F(49, 1617)=2.349, p<0.01), no significant interaction of trials and treatment groups 
(F(147, 1617)=1.084, p=0.241), and no significant differences between the treatment 
groups (F(3, 33)=0.389,p=0.761). At month 9, treatment groups showed habituation 
(F(49, 1421)=2.268, p<0.01), no significant interaction of trials and treatment groups 
(F(147, 1421)=0.959, p=0.621), and no significant differences between the treatment 
groups (F(3, 39)=0.251,p=0.885). At month 12, treatment groups showed habituation 
(F(49, 1274)=2.624, p<0.01), no significant interaction of trials and treatment groups 
(F(147, 1274)=0.912, p=0.759), and no significant differences between the treatment 
groups (F(3, 26)=1.391,p=0.268).  
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Figure 14: Short-term habituation at months 3, 6, 9, and 12 post-surgery 
Rats expressing either wt-tau, Thr175Asp-tau, Thr175Ala-tau, or EGFP (refer to 
Table 1 for n values).  Short-term habituation data at the (A) 3 month, (B) 6 
month, (C) 9 month, and (D) 12 month post-surgery time points. All four 
treatment groups showed habituation to the startle stimuli when presented with 
repeated trials. There was no significant interaction of trials and treatment 
groups, and there were no significant differences between the four treatment 
groups at any time point. Data are expressed as means.  
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3.3.2 Prepulse inhibition (PPI)  
Rats were tested for PPI with prepulse intensities of 85 and 75 dB. A prepulse intensity of 
85 dB produces a more robust and maximum PPI, whereas PPI with a 75 dB prepulse is 
more subtle. Both of these prepulse intensities were tested at two interstimulus intervals 
(ISI’s) of 30 and 100 ms. Different receptor subtypes have been suggested to mediate PPI 
at these different ISI’s (Yeomans et al. 2010).  
For the 85 dB prepulse, ANOVA followed by post hoc test with Bonferroni corrections 
revealed a significant effect of ISI at month 3 (F(1,34)=8.048, p<0.01), without a 
significant interaction of ISI and treatment (F(3,34)=1.788, p=0.168), and no significant 
differences between the four treatment groups (F(3, 34)=1.774, p=0.171) (Figure 15). At 
the subsequent time points there were no significant effects of ISI, treatment, or an 
interaction of ISI and treatment. At month 6 there was no significant effect of ISI 
(F(1,33)=0.242, p=0.626), no significant interaction of ISI and treatment (F(3,33)=1.207, 
p=0.322), and no significant differences between the four treatment groups (F(3, 
33)=0.513, p=0.676). At month 9 there was no significant effect of ISI (F(1,29)=1.350, 
p=0.255), no significant interaction of ISI and treatment (F(3,29)=0.449, p=0.720), and 
no significant differences between the four treatment groups (F(3, 29)=0.278, p=0.841). 
At month 12 there was no significant effect of ISI (F(1,26)=0.270, p=0.608), no 
significant interaction of ISI and treatment (F(3,26)=1.459, p=0.249), and no significant 
differences between the four treatment groups (F(3, 26)=0.153, p=0.927). 
For the 75 dB prepulse, ANOVA followed by post hoc test with Bonferroni corrections 
revealed a significant effect of ISI, without a significant interaction of ISI and treatment, 
and no significant differences between the four treatment groups at all time points (Figure 
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16). At month 3, there was a significant effect of ISI (F(1,34)=0.411, p<0.01), no 
significant interaction of ISI and treatment (F(3,34)=0.122, p=0.947), and no significant 
differences between the four treatment groups (F(3, 34)=0.507, p=0.680). At month 6, 
there was a significant effect of ISI (F(1,33)=9.048, p<0.01), no significant interaction of 
ISI and treatment (F(3,33)=0.559, p=0.646), and no significant differences between the 
four treatment groups (F(3, 33)=0.248, p=0.241). At month 9, there was a significant 
effect of ISI (F(1,29)=11.994, p<0.01), no significant interaction of ISI and treatment 
(F(3,29)=0.653, p=0.588), and no significant differences between the four treatment 
groups (F(3, 29)=0.274, p=0.844). At month 12, there was a significant effect of ISI 
(F(1,26)=30.301, p<0.01), no significant interaction of ISI and treatment (F(3,26)=1.149, 
p=0.348), and there no significant differences between the four treatment groups (F(3, 
26)=0.422, p=0.739). 
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Figure 15: PPI at 85 dB with ISI 30 and 100 ms at 3, 6, 9, and 12 months 
post-surgery 
Rats expressing either wt-tau, Thr175Asp-tau, Thr175Ala-tau, or EGFP (refer to 
Table 1 for n values).  Prepulse inhibition with a prepulse of 85 dB and 
interstimulus intervals (ISI) of 30 and 100 ms. (A) At month 3 post-surgery there 
was a significant difference between startle ISI 30 and 100 at 85 dB. There was 
no significant interaction of ISI and treatment, and there were no significant 
differences between the four treatments. There were no significant differences at 
the (B) 6 month, (C) 9 month, or (D) 12 month time points in terms of either ISIs 
or treatment groups. Data are expressed as means ± SEM. * indicates statistical 
significance, p<0.05.  
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Figure 16: PPI at 75 dB with ISI 30 and 100 ms at 3 months post-surgery 
Rats expressing either wt-tau, Thr175Asp-tau, Thr175Ala-tau, or EGFP (refer to 
Table 1 for n values). Prepulse inhibition (PPI) with a prepulse of 75 dB and 
interstimulus intervals (ISI’s) of 30 and 100 ms. At the (A) 3 month, (B) 6 
month, (C) 9 month, and (D) 12 month post-surgery time points there was a 
significant difference between startle ISI 30 and 100 at 75 dB. There were no 
significant interactions of ISI and treatment, and no significant differences 
between the four treatment groups at any given time point. Data are expressed as 
means ± SEM. * indicates statistical significance, p<0.05. 
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3.3.3 Longitudinal prepulse inhibition (PPI) 
Prepulse inhibition data was also analyzed across testing periods (months 3, 6, 9, and 12 
post-surgery) to assess for potential age effects. No effects of testing months were 
observed at either ISI 30 or ISI 100 for the 85 or 75 dB prepulses. For the 85 dB prepulse, 
ANOVA showed no significant effect of testing time point on ISI 30 (F(3,134)=1.465, 
p=0.227) or ISI 100 (F(3,134=1.812, p=0.148). For the 75 dB prepulse, ANOVA showed 
no significant effect of testing time point on ISI 30 (F(3,134)=2.096, p=0.104) or ISI 100 
(F(3,134)=1.318, p=0.271). 
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Figure 17: Longitudinal PPI at 85 dB and 75 dB  
Rats expressing either wt-tau, Thr175Asp-tau, Thr175Ala-tau, or EGFP (refer 
Table 1 for n values). Prepulse inhibition (PPI) with a prepulse of 75 dB and 
interstimulus intervals (ISI’s) of 30 and 100 ms at the 3, 6, 9 and 12 month time 
points. (A) PPI 85 dB. (B) PPI 75 dB. There was not a significant effect of time 
on PPI with ISI 30 or 100 at either 85 or 75 dB prepulse intensities. Data are 
expressed as means ± SEM.   
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3.4 Morris Water Maze Results 
3.4.1 Spatial learning in the Morris water maze  
To test for spatial learning and memory in the rats, the Morris water maze (MWM) was 
performed on months 1, 3, 6, 9, and 12 post-surgery. The protocol involved 4 spatial 
learning trials per day for 4 days. ANOVA revealed that all treatment groups were 
successful in learning the task after the 4 days of spatial learning as the latency to reach 
the platform decreased over the 4 testing days at each time point (representative data at 
month 12, Figure 19, F(3,78)= 13.337, p<0.01). There was not a significant difference in 
the time taken to find the platform over the 4 testing days between the treatment groups 
(representative graphs at month 12 testing shown Figure 19, F(3,26)=3.104, p=0.044). 
Additionally, multivariate ANOVA revealed a decrease in latency between testing 
months (F(16,628)=6.876, p<0.01), with no effect of treatment groups across the testing 
months (F(48,628)=1.101, p=0.301) (Figure 18).   
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Figure 18:  Mean latency to find platform across 4 learning days during 1, 3, 
6, 9, and 12 month post-surgery time points 
Rats expressing either wt-tau, Thr175Asp-tau, Thr175Ala-tau, or EGFP (refer to 
Table 1 for n values). Latency (s) to find platform over 4 learning days across 
testing months 1, 3, 6, 9 and 12 post-surgery. The latency depicted on each day is 
an average of 4 trials on that day. There was a significant decrease in latency 
between testing months, with no significant effect of treatment groups across the 
testing months. Data are expressed as means ± SEM. 
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Figure 19: Mean latency (s) to reach the platform during 4 learning days at 
month 12 post-surgery 
Rats expressing either wt-tau (n=6), Thr175Asp-tau (n=7), Thr175Ala-tau (n=8), 
EGFP (n=9). Mean time to find the hidden platform for each group over the 4 
consecutive learning days. Rats received 4 training trials per day. All animals 
learned the MWM task as performance improved across days of testing, but there 
was no significant effect of treatment. Data are expressed in means ± SEM.  
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3.4.2 Test of spatial memory using probe trials – Day 5     
A probe trial was conducted 24 hours after the 4 learning days in all cases. This involved 
the removal of the hidden platform from the water. Rats are given a total of 30 seconds in 
the Probe trial. Normal performance is expected to show a preference for the Quadrant 
that contained the platform during the learning trials. In terms of time spent in each 
quadrant, repeated measures ANOVA followed by post hoc paired t-test with Bonferroni 
corrections revealed that the four treatment groups did not explore all quadrants equally, 
they showed a preference for the target quadrant, and there were no significant 
differences between the groups at 1, 3, 6, and 9 month time points (Figure 20). At month 
1, subjects did not explore all quadrants equally (F(3,105)=26.058, p<0.01), with a 
preference for the target quadrant (Q1) over all others (Q2, Q3, Q4, t38=7.941, p<0.01, 
t38=4.446, p<0.01, t38=4.310, p<0.01, respectively) across all groups, and there was not 
a significant difference between the treatment groups (F(3,35)=0.209, p=0.890). At 
month 3, subjects did not explore all quadrants equally (F(3,90)=34.35, p<0.01), with a 
preference for the target quadrant (Q4) over all others (Q3, Q2, Q1, t37=4.4, p<0.01, 
t37=5.9, p<0.01, t73=6.7, p<0.01, respectively) across all groups, and there was not a 
significant difference between the treatment groups (F(3,30)=0.87, p=0.463). At month 6, 
subjects did not explore all quadrants equally (F(3, 99)=11.172, p<0.01), with a 
preference for the target quadrant (Q4) over all others (Q3, Q2, Q1, t36=5.877, p<0.01, 
t36=2.630, p<0.05, t36=4.720, p<0.01, respectively) across all groups, and there was not 
a significant difference between the treatment groups (F(3,33)=1.314, p=0.286). At 
month 9, subjects did not explore all quadrants equally (F(3,87)=35.568, p<0.01), with a 
preference for the target quadrant (Q3) over all others (Q4, Q2, Q1, t32=8.126, p<0.01, 
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t32=6.192, p<0.01, t32=7.272, p<0.01, respectively) across all groups, and no statistical 
differences between the treatment groups (F(3,29)=1.286, p=0.298). At the 12 month 
time point subjects did not explore all quadrants equally (F(3,78)=16.325, p<0.01), 
however there was a significant difference between the preferences of the four treatment 
groups (F(3,26)=3.427, p<0.05), and a significant interaction between treatment and 
quadrant (F(9,78)=2.831, p<0.05, Figure 20, Figure 21). There was a preference for Q4 
over all others (Q1, Q2, Q3, t29=5.8534, p<0.01, t29=3.079,p<0.01, t29=6.822, p<0.01, 
respectively) across all groups. Further, there were no significant differences between the 
groups in the time spent in the platform zone (F(3,29)=0.626,p=0.605) or area around the 
platform zone (F(3,29)=1.958,p=0.145, Figure 22C, E), nor was there a significant 
difference between the treatment groups in terms of the latency to find those zones 
(F(3,29)=1.949, p=0.147, F(3,29)=0.319, p=0.811,Figure 22D, F). The lack of differences 
between treatment groups in terms of time in the platform zone, time in the area around 
the platform zone, and latency to those zones held true at all testing time points.  
Note: “platform zone” refers to an area encompassed by the actual circumference of the 
platform, whereas the “area around the platform zone” refers to an area encompassed by 
a circle with a diameter twice the size of the platform zone, with the platform zone at the 
center. The area around the platform zone is used to account for the fact that the 
ANYMAZE tracking system uses only a single point on the rat to track its movement, 
and this point may sometimes be out of the platform zone, when part of the rat is in fact 
in the zone.   
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Figure 20: Time spent in each quadrant on probe trial day 5 at months 1, 3, 
6, 9, and 12 of behavioural testing 
Rats expressing either wt-tau, Thr175Asp-tau, Thr175Ala-tau, or EGFP (refer to 
Table 1 for n values).This figure is included to depict the day 5 probe trials at the 
1, 3, 6, 9 and 12 month behavioural time points. Statistics were not performed on 
this longitudinal graph.  
0
2
4
6
8
10
12
14
16
w
t-
ta
u
T
h
r1
7
5
A
s
p
-t
a
u
T
h
r1
7
5
A
la
-t
a
u
E
G
F
P
w
t-
ta
u
T
h
r1
7
5
A
s
p
-t
a
u
T
h
r1
7
5
A
la
-t
a
u
E
G
F
P
w
t-
ta
u
T
h
r1
7
5
A
s
p
-t
a
u
T
h
r1
7
5
A
la
-t
a
u
E
G
F
P
w
t-
ta
u
T
h
r1
7
5
A
s
p
-t
a
u
T
h
r1
7
5
A
la
-t
a
u
E
G
F
P
w
t-
ta
u
T
h
r1
7
5
A
s
p
-t
a
u
T
h
r1
7
5
A
la
-t
a
u
E
G
F
P
Month 1 Month 3 Month 6 Month 9 Month 12
T
im
e
 (
s
) 
Target Quadrant
CW to target
Opposite to target
CCW to target
61 
 
 
 
 
Figure 21: Time spent in each quadrant during probe trial day 5 at 12 
months post-surgery 
Rats expressing either wt-tau (n=6), Thr175Asp-tau (n=7), Thr175Ala-tau (n=8), 
or EGFP (n=9). Total time spent in each quadrant during the Probe trial (24 hours 
after the last learning day), where the hidden platform is removed from the 
MWM. Quadrant 4 (Q4) is the quadrant where the platform used to be. Rats are 
given a total of 30 seconds in the probe trial. Normal performance is expected to 
show a preference for the Quadrant that contained the platform during the 
learning trials. Subjects did not explore all quadrants equally. There is a 
statistical difference between the preferences of the four treatment groups, and a 
significant interaction between treatment and quadrant.  
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Figure 22: No significant differences in performance between treatment 
groups during probe trial day 5 
Rats expressing either wt-tau (n=6), Thr175Asp-tau (n=7), Thr175Ala-tau (n=8), 
or EGFP (n=9). There was no significant effect of treatment on (A) average swim 
speed, (B) total distance traveled, (C) time spent in the platform zone, (D) latency 
to reach platform zone, (E) time spent in the area around the platform, or (F) 
latency to the area around the platform during probe trial day 5 at month 12 post-
surgery. Data are expressed as means ± SEM.  
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3.4.3 Cognitive flexibility in the reversal trials 
At the 12 month time point, reversal learning trials were added to the MWM protocol to 
control for repeated testing, and to potentially observe any differences in treatment 
groups that were not apparent through other protocols. The protocol involved the normal 
4 days of learning, with a probe trial on the 5
th
 day, followed by a reinforcement trial 
(where the platform was placed back in its original location, Day 5b), and then the 
reversal trials, where the platform was placed in the opposite quadrant (Days 6a and 6b). 
This was to test the rats’ cognitive flexibility. Each treatment group showed a similar 
increase in time to find the platform when the platform location was changed, and 
ANOVA revealed a steep decrease in time to find the new platform location over 4 initial 
trials (F(3,75) = 7.323, p<0.01, Figure 23). There was no difference in learning the new 
platform location between the treatment groups (F(3,25)=1.691, p=0.195).  
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Figure 23: Latency during reversal trials 
Rats expressing either wt-tau (n=6), Thr175Asp-tau (n=7), Thr175Ala-tau (n=8), 
EGFP (n=9). This graph shows the latency to find the new platform location 
during the reinforcement trials (Day 5b), the first day of reversal learning (Day 
6a), and the second set of reversal trials (Day 6b). All treatment groups 
successfully learned the location of the new platform, as performance improved 
across trials on the first set of reversal trials. There was no significant difference 
in learning between the four treatments at month 12 post-injections. Data are 
expressed in means.  
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3.4.4 Mean speed in the Morris water maze 
The mean swim speed of each rat was also assessed in the water maze. Mean speed acts 
as an indicator for the rats’ ability to swim since it may influence the latency to reach the 
platform on any given testing day, and is an important control to ensure for no motor 
deficiencies. ANOVA revealed no significant differences between treatment groups 
(F(3,25)=0.318, p=0.812), and no significant change in mean speed over the 4 learning 
days (F(3,75) = 2.064, p=0.112 (representative graph for Month 12 incorporated in 
Figure 24).  
Interestingly, there was an increase in mean speed over the testing days during month 12 
post-surgery (F(6,150) = 5.062, p<0.01), with no significant difference between the 
treatment groups (F(3,25)=0.335, p=0.800, Figure 24). It is important to note that the 12 
month time point was the first and only time that the rats had been tested in the MWM for 
7 consecutive days as previous protocols did not require so many days.  
Further, with repeated testing there was no significant effect of testing time points on 
mean swim speed (F(4,157)=0.482, p=0.749, Figure 25), and no significant effect of 
treatment groups (F(12,157)=0.869, p=0.579) in terms of the 4 learning days over months 
1, 3, 6, 9 and 12. 
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Figure 24: Mean speed over all testing days excluding probe trials at month 
12 post-surgery  
Rats expressing either wt-tau (n=6), Thr175Asp-tau (n=7), Thr175Ala-tau (n=8), 
EGFP (n=9). Mean speed during 4 days learning, reinforcement day (after probe 
1), and 2 reversal days (before probe 2). Rats received 4 trials per day. There was 
a significant effect of day on mean speed, and from the figure it can be seen that 
mean speed increased over testing days. There was no significant difference in 
mean speed between treatment groups at 12 month post-injection. In terms of the 
4 learning days, there was no significant effect of day on mean speed, and no 
significant difference between treatment groups. Data are expressed in means ± 
SEM. 
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Figure 25: Mean swim speed of 4 learning days over 1, 3, 6, 9, and 12 month 
post-surgery time points 
Rats expressing either wt-tau, Thr175Asp-tau, Thr175Ala-tau, or EGFP (refer to 
Table 1 for n values). Average speed of the 4 learning days in the MWM at 1, 3, 
6, 9 and 12 months post-surgery. Each month consisted of 4 learning days, with 4 
learning trials per day. Thus, these averages are calculated by taking the average 
speed over the 4 trials for each of the 4 learning days, then averaging the 4 
learning days for the month. There was no significant difference in mean speed at 
the different testing time points, and no significant difference between treatment 
groups across testing time points. Data are expressed in means ± SEM. 
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4. Discussion  
Microtubule associated tau protein (tau) pathology is evident in ALS with frontotemporal 
dysfunction. Previous studies have shown that ALSci is associated with atrophy of 
frontotemporal lobes, neuronal and extraneuronal tau deposition, and a unique tau 
phosphorylation site at Threonine residue 175 (pThr175-tau) (Strong et al. 2006; Wilson 
et al. 2001; Yang et al. 2003, 2005). The aberrant phosphorylation of tau protein at 
Thr175 is hypothesized to play a role in the pathogenesis leading to the cognitive 
impairment in ALS (Gohar et al. 2009; Strong et al. 2006). Here, an in vivo rat model has 
been established to test the behavioural consequences of expression of an aberrantly 
phosphorylated tau mimic (Thr175Asp-tau) in the hippocampus of Sprague Dawley rats. 
It has been demonstrated in this study that injection of Thr175Asp-tau construct, as well 
as controls (wt-tau, Thr175Ala-tau, EGFP), into the hippocampus using the rAAV9 gene 
transfer technique allows for expression in the hippocampus that is maintained for the 12 
month testing period (Figure 2, Figure 3). Initial histology shows some presence of tau 
fibrils in the Thr175Asp-tau group at 3 months post-injections (Figure 4). Further 
detailed analysis of tau expression will be conducted, but is not part of this thesis. 
In this study, in spite of the induction of tau pathology, we have failed to observe a 
behavioural phenotype when comparing the experimental Thr175Asp-tau–expressing rat 
group to controls (wt-tau, Thr175Ala-tau, EGFP) at any given time point (1, 3, 6, 9, or 12 
months post-surgery). Open-field testing (OFT) revealed normal exploratory behaviour 
that habituated over time (Figure 11 - Figure 13), while startle testing showed short-term 
habituation (STH) to an acoustic stimulus (Figure 14), and normal levels of prepulse 
inhibition (PPI, Figure 15, Figure 16) in all four groups. Lastly, the Morris water maze 
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(MWM) did not reveal any deficits in spatial learning or memory in the Thr175Asp-tau-
expressing rat group when compared to controls (Figure 18 - Figure 22). 
4.1 Viral vector expression in the rat hippocampus 
In our study, the bilateral stereotactic hippocampal injections of the rAAV9 constructs 
exhibited expression of human tau protein in the hippocampus of the treatment groups 
(Figure 2, Figure 3). This was visualized through immunohistological staining for green 
fluorescent protein (GFP). These findings substantiate previous studies demonstrating 
that intraparenchymal injections of AAV9 to the central nervous system (CNS) shows 
efficient expression of the protein of interest, and serves as a highly efficient vector for 
neurons (Klein et al. 2009; McCown 2005). Further, it has been previously established 
that this method is an operational mechanism for neuropathological expression of tau 
protein in specific brain regions (Klein et al. 2009). With this, the viral load size used in 
this experiment seems effective in leading to widespread expression in the hippocampus 
that is sustained throughout the entire 12 month study (Figure 3). Both the amount of 
virus, and method of injection into the hippocampus have been verified in the literature 
using both mutated tau, and through lentiviral gene transfer models (Herman et al. 2011; 
Mustroph et al. 2012).  
4.2 Normal exploratory behaviour and lack of anxiety-like behaviour 
In our OFT analysis, the Thr175Asp-tau rats showed normal levels of exploratory 
behaviour, and habituation of exploration over 30 minutes in the open field box at all 
time points (1, 3, 6, 9, and 12 months post-surgery) with no significant difference from 
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controls (representative figure at month 12, Figure 11). This indicates that there is no 
difference in motor activity between treatment groups (Seibenhener and Wooten 2015). 
Further, in this study, the four treatment groups did not display differences in anxiety-like 
behaviour, measured as the ratio of the time spent in the center of the box versus the 
periphery (Figure 13, Seibenhener and Wooten 2015). These results are important to also 
validate subsequent behavioural testing for cognitive function, which can easily be 
confounded by differences in motor ability or anxiety (Seibenhener and Wooten 2015).  
Unfortunately, the testing location and the open field boxes themselves were changed at 
one point during testing. A move of the animal facility into a new building took place 
after the testing points of 1 and 3 months post-surgery, and before the 6 month time point. 
However, when comparing the 6, 9, and 12 month time points, each treatment group 
traveled a significantly smaller distance with repeated testing in the same boxes (Figure 
12). This indicates that the animals showed long-term habituation of the locomotor 
activity upon repeated testing in the same boxes. Alternatively, the longer distance 
traveled at month 6 may have occurred because of the move to a new animal facility as 
well as a change in testing apparatus, indicating a sensitivity of the OFT to changing 
emotions in rats. In any case, there were not any significant differences between the 
treatment groups at any given time point. This similarity in total distance traveled shows 
similar locomotor activity between treatment groups and, again, eliminates confounding 
factors when analyzing other behavioural results (Seibenhener and Wooten 2015).  
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4.3 Acoustic startle response (ASR), prepulse inhibition (PPI) and short-term 
habituation (STH) 
The acoustics startle response (ASR) is a protective reflex stimulated by a sudden 
acoustic stimulus. In rodents, the startle response involves a whole body flinch. Testing 
the ASR is a behavioural paradigm used to assess sensory filtering and sensorimotor 
gating, and can aid in indicating neurodegenerative disease or cognitive impairments 
through investigation of habituation and prepulse inhibition (PPI) (Van den Buuse 2010; 
Davis and Wagner 1969; Fenton, Stover, and Insel 2003; Geyer 2006; Valsamis and 
Schmid 2011).  
Habituation is a form of non-associative learning that involves a decreased response to a 
repeated stimulus, and is a form of sensory filtering. Short-term habituation (STH) is 
habituation within a testing session (Davis and Wagner 1969). In our study, the four 
treatment groups exhibited STH to a repeatedly presented acoustic stimulus with no 
significant differences between groups (Figure 14). This was indicative of intact sensory 
filtering, with no indications of disruptions in habituation. Disruptions in habituation 
could be suggestive of mental or neurodegenerative disease (Davis and Wagner 1969; 
Valsamis and Schmid 2011). If significant neurodegeneration were present in any 
particular treatment group in this study, slower habituation, or no habituation at all would 
likely be observed (Braff, Geyer, and Swerdlow 2001; Kumari et al. 1999).  
PPI is the inhibition of a startle response to a startle stimulus, when the startle stimulus is 
preceded by a weak prestimulus, or prepulse (Hoffman and Ison 1980; Koch 1999; 
Swerdlow, Geyer, and Braff 2001). Prepulse inhibition is a form of sensorimotor gating, 
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meaning it is assumed that the prepulse elicits an orienting response while avoidance 
responses such as startle are inhibited (Fendt, Li, and Yeomans 2001). PPI has been 
shown to be disrupted in many mental disorders and neurodegenerative diseases (Van den 
Buuse 2010; Fenton et al. 2003; Geyer 2006; Swerdlow and Geyer 1998). Although PPI 
is mediated by midbrain circuits, it is modulated by the hippocampus. Therefore 
examination of the startle response was important to assess the function of the 
hippocampus (Caine, Geyer, and Swerdlow 1992; Fendt et al. 2001; Jones and Shannon 
2000; Li et al. 1998; Mawr 1985; Swerdlow et al. 1993; Yeomans, Hempel, and 
Chapman 1993). There is evidence of regional heterogeneity throughout the hippocampal 
formation as to the degree to which they modulate PPI and sensory filtering (Caine et al. 
1992). Specifically, the CA1, dentate gyrus (DG), and ventral subiculum have been 
implicated in differing abilities to modulate PPI and the ASR when presented with 
cholinergic agonists and antagonists (Caine et al. 1992). Considering this, it will be 
interesting to draw potential correlations between tau expression patterns in single rats 
and the amount of PPI in the respective animals upon further detailed histological 
analysis.  
Here, by assessing average group performance, we observed no indications of deficits in 
PPI at either 85 or 75 dB prepulse intensities in any treatment groups at any given testing 
time points (Figure 15, Figure 16). With an 85 dB prepulse, there was a significant 
difference between the interstimulus intervals (ISI) 30 and 100 ms at the 3 month time 
point, but not at the subsequent time points (6, 9, 12 months, Figure 15). On the other 
hand, there was a significant difference between the ISI’s of 30 and 100 ms for all testing 
points (3, 6, 9, and 12 months) for PPI at 75 dB, with the 30 ms ISI exhibiting 
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significantly lower PPI than 100 ms (Figure 16). Therefore, a prepulse intensity of 85 dB 
allows for maximal PPI, whereas 75 dB does not. This is not unexpected as PPI is 
enhanced with increasing intensities, and 85 dB is a higher intensity than 75 dB 
(Hoffman and L 1970; Hoffman and Searle 1968).  
Furthermore, PPI at different ISI ranges act through differing mechanisms. Ionotropic 
receptors mediate the fast (ISI’s of 10-100 msec) effects of PPI, where metabotropic 
receptors mediate the long-lasting (ISI’s of 100-1000 msec) effects of PPI (Jones and 
Shannon 2000; Yeomans et al. 2010). The purpose of measuring two different ISI’s in 
this study was to gain an understanding of what type of transmitter system was affected 
in case there was a deficit in the experimental group. Ultimately, our results presented 
here as group averages are not indicative of any abnormalities in sensory filtering, or 
cognitive impairment caused by expression of the different tau constructs. Further 
analysis correlating the expression patterns of the constructs with PPI performance in 
single animals, however, might be more sensitive to subtle changes (Van den Buuse 
2010; Fenton et al. 2003; Geyer 2006; Swerdlow and Geyer 1998). 
When analyzing PPI across all testing time points (3, 6, 9, and 12 months post-surgery), 
there seems to be a trend towards decreasing PPI at 75 dB prepulse intensity across time 
that is not as apparent at 85 dB prepulses (Figure 17). Though this trend is not 
statistically significant, this observation may imply the onset of hearing loss in the aged 
rats, and thus variability in their ability to hear the lower intensity 75 dB prepulse.   
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4.4 Spatial learning, reference and working memory 
From our MWM data, it is important to firstly note that there were no significant 
differences in mean speed between treatment groups, and the mean speed did not 
significantly change with repeated testing (Figure 24, Figure 25). From this, it can be 
inferred that swim speed did not play a role on latency measures. Interestingly, at the 12 
month time point the rats were tested for 7 consecutive days, and there was a significant 
increase in mean speed for all treatment groups over those 7 days (Figure 25). This was 
the only time the rats had been tested for such a high number of consecutive days, and is 
an indication that the rats were still motivated in finding the hidden platform.  
We had hypothesized that the expression of Thr175Asp-tau would cause 
neurodegeneration and thereby significant damage to the hippocampus. This would result 
in deficits in reference memory because it involves consolidation of memories, a function 
of the hippocampus (Giap 2000; Vorhees and Williams 2006). In our MWM task, we 
found that the Thr175Asp-tau group, along with the control groups showed intact spatial 
learning through a trend of decreasing time to find the platform on learning days (Figure 
19), and displayed intact reference memory through a low latency to the platform zone on 
probe trials (Figure 22). This occurred at all time points (1, 3, 6, 9, and 12 month post-
surgery).  
One abnormality to note is that on probe trial day 5 at the 12 month post-surgery time 
point, the EGFP treated group showed preference for the quadrant opposite to the target 
quadrant, where the other groups showed a preference for the target quadrant (Figure 21). 
Upon further analysis, a similar trend can be observed in the EGFP group at the month 1 
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and 6 time points post-surgery (Figure 20). It is unlikely that this is indicative of a 
behavioural phenotype, as there was no significant difference in the latency to find the 
platform zone between the treatment groups on probe day 5 (Figure 22). A likely 
explanation is that rats in the EGFP group abandoned looking for the platform in the 
original location once it was realized that the platform was not present in that location.  
Interestingly, with repeated testing (at the 1, 3, 6, 9, and 12 month post-surgery time 
points), the rats seemed to improve on the MWM task, as indicated by decreasing 
latencies to find the platform over time points (Figure 18). To control for repeated testing, 
the MWM protocol was extended to include reversal learning at the 12 month time point 
to test working memory and behavioural flexibility. All treatment groups showed a rapid 
adaptation to the new platform location within the first day of testing without significant 
differences between groups (Figure 23). Reversal learning was used to enhance the 
detection of spatial impairments as it requires the animal to extinguish the existing 
knowledge of the original platform location and adapt to the new location by using 
information from the immediate past (Bradley and Hitch 1974; Vorhees and Williams 
2006). This form of cognitive flexibility has shown to be a more sensitive test than the 
classic form of spatial learning in the water maze (Al-onaizi et al. 2016; Vorhees and 
Williams 2006). If deficits in working memory were present, the rats would likely also 
not adapt to the new platform location as rapidly as observed here (Figure 23).  
The above results may be an indication of a lack of pathology in the hippocampus, or 
pathology that is not present in the regions of the hippocampus necessary for spatial 
learning and memory. It has been shown that both the extent and region of damage within 
the hippocampal formation are factors that influence behavioural outcomes in tests such 
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as the MWM (Morris et al. 1982; Moser, Moser, and Andersen 1993). Specifically, the 
dorsal hippocampus plays a greater role in spatial navigation than the ventral 
hippocampus (Moser et al. 1993). It has been previously shown that a widespread tau 
pathology is required to lead to spatial memory deficits in rats (Mustroph et al. 2012). 
Mustroph et al. showed that deficits in the MWM correlated with robust expression in the 
hippocampus proper via rAAV9 viral vector, the presence of neurofibrillary tangles 
(NFT’s) throughout the hippocampus, extensive hyperphosphorylated tau, and profound 
neuronal loss detected in tau-expressing cells (2012). Altogether, this indicates that 
pathology in the dorsal hippocampus may be of greater interest to correlate with MWM 
behavioural data than in the ventral hippocampus, and that pathology needs to be 
widespread and severe in order to result in a behavioural phenotype.    
4.5 Possible explanations for lack of behavioural deficits 
It must be emphasized that tissue staining of all rat brains in this study is still underway 
and has not yet been completed. A more advanced analysis of behavioural results is 
contingent upon the completion of this histology and subsequent correlation of tau 
expression patterns and behavioural phenotype. The results obtained here may have 
occurred because of the following reasons: (1) the construct expression within the 
hippocampus may not have been robust enough to lead to pathological tau fibril 
formation throughout the entirety of the hippocampus, (2) there may not have been 
enough time for the expression of the tau construct to lead to pathological fibril 
formation, subsequent neurodegeneration and a behaviourally measurable pathology, (3) 
the presented hypothesis of pThr175-tau playing a role in the frontotemporal syndromes 
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in ALS may be incorrect, or (4) there may be a need for tandem pathology of both TDP-
43 and tau. Each of these reasons will be explained here. 
First, expression of tau constructs in the hippocampus have been demonstrated (Figure 2, 
Figure 3), and tau fibrillary structures have been identified in an experimental group 
(Thr175Asp-tau) at month 3 post-surgery (Figure 4). However, tau construct expression 
was not consistently widespread throughout the hippocampus (Figure 5). The extent of 
these observed fibrils is not yet known and it must be verified that this is an observation 
limited to the experimental group alone. It is also unknown if these fibrils are correlated 
with activation of proteins related to tau pathology such as increased expression of 
activated GSK3β, or increased caspase-3 activity (Moszczynski et al. 2015). Overall, the 
extent of construct expression may not be widespread throughout the hippocampal 
structure, and so the degree of resulting tau fibrillary pathology may not be sufficient to 
result in a behavioural phenotype. As has been explained in detail in earlier parts of this 
discussion, the regions of the hippocampus where pathology is taking place, and the 
extent of that pathology play vital roles in interpreting behavioural data.  
The second reason posited was that there may not have been enough time for the 
expression of the tau construct to lead to pathological fibril formation. With the above in 
mind, it is also important to consider the fact that this study ended at the 12 months post-
surgery time point. If pathology is not present, there is the possibility that 12 months does 
not provide sufficient time to lead to a behavioural phenotype with the given tau 
construct. As outlined in the introduction section of this paper, a potential pathway was 
described where pThr175-tau induces GSK3β activation, which leads to Thr231 
phosphorylation and subsequent fibril formation (Moszczynski et al. 2015). Since it is 
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likely that pThr175-tau plays an indirect, or an initiating, role in the mechanism leading 
to the observed frontotemporal dysfunction in ALS, there is potential for this mechanism 
of pathology to take longer than 12 months to lead to a behaviourally measurable 
phenotype in the rat model.   
The third potential reason is that there is the possibility that the original hypothesis of 
pThr175-tau playing a role in the neurodegeneration and resulting cognitive impairments 
in ALS is, in fact, incorrect. To assess if there were any true differences between the four 
treatment groups, the brains of these rats will have to be analyzed for potential pathology, 
degeneration, and upregulation of specific proteins. Again, this will be further 
investigated with staining, and histological analysis.  
Lastly, there may be a need for tandem pathology of TDP-43 as well as tau in order to 
observe a behavioural phenotype. Though there is abundant evidence of pathological 
alterations in tau metabolism in ALSci, TDP-43 pathological processing is also a 
significant component of the pathology of ALS (Geser et al. 2013; Ince et al. 2011). Thus 
it is unclear whether the observed tau pathology in the frontotemporal syndromes of ALS 
is a primary or secondary phenomenon, and if secondary, whether it is driven by the 
altered TDP-43 metabolism observed in ALS.   
4.6 Study Limitations 
There are a number of limitations to this study, such as a rapid decrease in the health of 
our rats after the 6 month post-surgery time point, the lack of histological staining, and 
potential variability in expression patterns. 
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A major limitation faced in this study was a rapid decline in health in many of the rats 
over time. There were sporadic health issues in the initial phases of the experiment, such 
as the death of a rat as early as 1 month after surgery from respiratory disease, and 
another rat suffered a non-operable tumour and was sacrificed approximately 3 months 
after surgery. One additional rat died of respiratory issues 7 months post-surgery. The 
most damaging issue in terms of the health of the rats was the development of tumours in 
a large portion of the rats after the 6 month time period. Specifically, 5 rats developed 
tumours approximately 9 months post-surgery, and an additional 6 rats developed 
tumours at approximately 12 months post-surgery. These tumours were inconsistent in 
both size and anatomical locations. The tumour locations included brain, oral, mammary, 
and genital sites. There was no evident correlation between treatment groups and 
development of tumours. The distribution of treatment groups to number of rats that 
eventually developed tumours are as follows: wt-tau; 4 rats, Thr175Asp-tau; 3 rats, 
Thr175Ala-tau; 2 rats, EGFP; 3 rats. Tissue analysis of the tumours confirmed that there 
was no viral expression in the tumours, and thus did not result from the rAAV9 
injections.  
Ultimately, this decline in health, which escalated after the 6 month testing period, 
prevented the study from being carried out past the 12 month time point. It also likely 
contributed to increased variability in the behavioural data in more than one way. Firstly, 
some rats were unhealthier than others, and this can lead to differing performances in the 
sensitive behavioural tasks conducted. Secondly, poor health lead to the early death of 
some rats, resulting in a decreased sample size in each group, which, again, increases 
variability in the data. To correct for this, we had performed a second round of 8 
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surgeries (2 rats per treatment group), to undergo behavioural testing at the 1, 3, 6, 9, and 
12 month post-surgery time points and the data is to be merged from these two cohorts.  
In addition to the poor health of the animals in this study, another major limitation is the 
lack of detailed histological analysis at this time point, which inevitably limits the 
behavioural analysis. With only the behavioural data we are limited in our analysis to 
assessing averages within treatment groups. Once the histological analysis has been 
completed, the behavioural data can be revisited using regression analysis to correlate 
behaviour with expression levels on an individual rat basis.    
Another possible limitation to this study is variable expression patterns in the 
hippocampus. The staining that has been conducted, though minimal, typically shows 
widespread expression of GFP throughout the given slice of hippocampal formation 
(Figure 2). However, some brain slices reveal expression primarily in the DG and CA3-
CA2 regions, with minimal expression in the remaining hippocampal structures, such as 
CA1 (Figure 5). With this, it is crucial to speculate that there may be variable expression 
from one injection to the next, and possibly variability in rostral-caudal expression since 
all injections were administered in one plain (A/P 5.5 mm caudal from bregma). These 
possibilities will be investigated once extensive staining of all rat brain slices is 
conducted.    
4.7 Future Studies  
In this study we have demonstrated a lack of behavioural differences in the experimental 
Thr175Asp-tau group compared to controls (wt-tau, Thr175Ala-tau, EGFP) after 12 
months of Thr175Asp-tau expression in the hippocampus. The immediate future studies 
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include the use of a transgenic ALS-like rat model, and one that examines methods of 
inhibiting tau pathology that may result from pThr175-tau.  
Currently, a double-transgenic Sprague Dawley rat line is being established to further 
investigate the role of pThr175-tau in a rat model with an ALS-like phenotype. The 
double transgenic (chat-tTA/TRE-TDP-43 M337V) rats will express human mutant TDP-
43 in a suppressible manner under doxycycline control. As mentioned in the introduction, 
the pathological processing of TDP-43 is a significant component of the pathology of 
ALS (Geser et al. 2013; Ince et al. 2011). The conditional expression of ALS-associated 
mutant TDP-43 (M337V) in rats results in motor neuron phenotype, without evidence of 
brain involvement (Huang et al. 2012). The same bilateral hippocampal injections of 
rAAV9 with tau constructs will be administered to these rats. The idea is to investigate 
whether pThr175-tau is the primary pathogenic insult in the frontotemporal syndromes of 
ALS, or whether it is a consequence of the altered TDP-43 metabolism observed in ALS. 
Ultimately, this will serve to determine whether the associated disease process is 
modified by the expression of mutant human TDP-43.  
Further, if there is a pathological effect of Thr175Asp-tau, it will be important to test 
methods of inhibiting the resulting pathology. It has already been established in cell 
culture that Thr175Asp-tau leads to upregulation of active GSK3β, which leads to 
subsequent tau phosphorylation and pathology (Moszczynski et al. 2015). If this 
mechanism holds true in our rat model, it will be important to investigate the effects of 
inhibitors of GSK3β in vivo. Eventually, the development of pharmacotherapies that 
target GSK3β may be critical to the resolution of pathological tau aggregates in ALS.  
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PART 5: SUMMARY AND CONCLUSIONS 
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5. Summary and Conclusions 
5.1 Summary of findings 
 rAAV9 viral vector injections lead to robust expression of GFP, and thus 
expression of the wt-tau, Thr175Asp-tau, Thr175Ala-tau, and EGFP constructs 
within the hippocampus of the Sprague Dawley rats (Strong Lab, unpublished 
data) 
 Expression was maintained for the entirety of the study (12 months post-surgery) 
in all treatment groups (Strong Lab, unpublished data) 
 Tau fibrillary structures have been observed in the Thr175Asp-tau group 3 
months post-surgery 
 Thr175Asp-tau group showed normal habituation of exploratory behaviour, no 
differences in total distance traveled, and no differences in anxiety-like behaviour 
at the 1, 3, 6, 9, and 12 month post-surgery time points when compared to 
controls (wt-tau, Thr175Ala-tau, EGFP) in the OFT 
 Thr175Asp-tau group showed normal short-term habituation at the 3, 6, 9, and 12 
month post-surgery time points when compared to controls (wt-tau, Thr175Ala-
tau, EGFP), and no deficits in PPI were observed between the groups using the 
acoustic startle response 
 Thr175Asp-tau group showed normal spatial learning and memory through 
learning trials, probe trials, and reversal trials in the MWM when compared to 
controls (wt-tau, Thr175Ala-tau, EGFP) 
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5.2 Conclusions 
This study demonstrated that Thr175Asp-tau expression throughout the hippocampus of 
non-transgenic Sprague Dawley rats does not lead to significant behavioural changes 
when compared to controls (wt-tau, Thr175Ala-tau, EGFP) up to 12 months post-surgery. 
There was expression throughout the hippocampus, and expression was maintained for 
the entirety of the experiment. It is therefore assumed that the gene transfer technique 
using rAAV9 viral vector was successful. However, the Thr175Asp-tau experimental 
group exhibited normal habituation of exploratory behaviour, and a lack of an anxiety-
like phenotype in the OFT. The experimental group also showed normal short-term 
habituation and lack of PPI deficits through ASR testing. Finally, the Thr175Asp-tau 
group showed normal spatial learning and memory in the MWM task, as well as normal 
cognitive flexibility. Ultimately, there were no measurable hippocampal or behavioural 
deficits observed in this study.  
Our findings also showed tau fibrillary structures in the experimental group at the 3 
month post-surgery time point. The extent of this pathology and whether or not it is 
limited to the experimental group will be further investigated with the histological 
analysis. This study proposes a possible mechanism for the frontotemporal dysfunction in 
ALS where tau protein pathology plays a critical role. Aberrantly phosphorylated tau at 
Thr175 is observed in this disease process, and is a potential mediator in the observed 
pathology. It is crucial to understand potential influence of pThr175-tau on the 
syndromes of frontotemporal dysfunctions in ALS in vivo. These results, and the results 
from the studies to immediately follow, will help to further our understanding of the 
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mechanism behind this complex disease process, and provide insight for novel 
pharmacotherapy targets.  
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